within Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX15_Inotersen;
model Inotersen 
   extends Pharmacolibrary.Drugs.ATC.N.N07XX15;

  annotation(Documentation(
    info ="<html><body><p>Inotersen is an antisense oligonucleotide that selectively inhibits hepatic transthyretin (TTR) production. It is used for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) in adults, where it reduces TTR protein levels to mitigate disease progression. Inotersen is approved for clinical use in several countries.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with hereditary transthyretin amyloidosis; results based on data compiled from clinical studies, most notably the NEURO-TTR trial. Parameters refer to subcutaneous dosing in adults of either sex.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Inotersen;
